Venture startup

Who invested in SK biopharmaceuticals

2 rounds we have observed, with the 4 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

Undisclosedraised across 2 rounds since 2012, from 2 sources

Latest round
VentureNov 2022
Investors
4
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

201220142016201820202022
?Round?Venture
First round
Round
Mar 2012
Between rounds
10.7 years
from the last two

The rounds

  1. Nov 2022
    VentureAmount undisclosed3 new

    Source recorded

  2. Mar 2012
    RoundAmount undisclosed1 new

    Reported by finsmes.com

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Everyone who backed them

Goldman SachsPrivate equity1round
KB InvestmentVC firm1round
MubadalaPrivate equity1round
Korea Drug Development FundInvestment firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about SK biopharmaceuticals

Who invested in SK biopharmaceuticals?

SK biopharmaceuticals's investors include Goldman Sachs, KB Investment, Mubadala and Korea Drug Development Fund.

How much has SK biopharmaceuticals raised?

SK biopharmaceuticals has raised 2 rounds since 2012, none with a disclosed amount.

When did SK biopharmaceuticals last raise?

SK biopharmaceuticals's most recent round was a Venture in Nov 2022.

Who backed SK biopharmaceuticals first?

SK biopharmaceuticals's first round on record, in Mar 2012, was backed by Korea Drug Development Fund.

What stage is SK biopharmaceuticals at?

SK biopharmaceuticals's latest named round is a Venture, in Nov 2022.

Companies like SK biopharmaceuticals

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.